Top entities: Zevra Therapeutics, MIPLYFFA, United States — Food and Drug Administration, United States — United States Patent and Trademark Office, Neil F. McFarlane.

What category does this event fall under?

Regulatory — classified as patent listing.

What is the sentiment of coverage?

Aggregate sentiment score: 40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Regulatory patent listing

Zevra Therapeutics Extends MIPLYFFA Patent

Q: When did this event occur?

First reported Jun 08, 2026; last updated Jun 08, 2026.

Q: What is the market impact?

General. The listing of the new patent for MIPLYFFA in the Orange Book extends its market exclusivity, which is positive for Zevra Therapeutics' stock price and long-term revenue prospects.

Analysis based on 6 articles · First reported Jun 08, 2026 · Last updated Jun 08, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The listing of the new patent for MIPLYFFA in the Orange Book extends its market exclusivity, which is positive for Zevra Therapeutics' stock price and long-term revenue prospects. This move reduces the threat of generic competition for MIPLYFFA, a key product for Zevra Therapeutics.

Pharmaceuticals Biotechnology

Event Summary

Zevra Therapeutics announced the submission of U.S. Patent No. 11,707,456 for its drug MIPLYFFA to the United States — Food and Drug Administration for listing in the Orange Book. This patent provides intellectual property protection until November 19, 2041, significantly extending the exclusivity for MIPLYFFA, a therapeutic option for Niemann-Pick disease type C. Neil F. McFarlane, President and CEO of Zevra Therapeutics, highlighted that this action strengthens the company's intellectual property portfolio and aims to maximize the drug's long-term value. Additionally, Zevra Therapeutics has a pending application with the United States — United States Patent and Trademark Office for a patent term extension for an earlier patent, U.S. Patent No. 11,045,460, which is set to expire in 2029.

Entities Involved

stock

Zevra Therapeutics

Zevra Therapeutics has strengthened its intellectual property protection for MIPLYFFA by submitting a new patent for Orange Book listing, extending its exclusivity until 2041. This action aims to maximize the long-term value of the drug and support patients with Niemann-Pick disease type C.

Importance 100.0 Sentiment 50.0

oth

MIPLYFFA

MIPLYFFA is a therapeutic option for Niemann-Pick disease type C, and its patent protection has been extended until 2041, enhancing its market value.

Importance 90.0 Sentiment 50.0

govactor

United States — Food and Drug Administration

The United States — Food and Drug Administration is the agency responsible for listing patents in the Orange Book, which provides regulatory exclusivity for drugs like MIPLYFFA.

Importance 70.0 Sentiment 0.0

govactor

United States — United States Patent and Trademark Office

The United States — United States Patent and Trademark Office is currently reviewing Zevra Therapeutics' application for a patent term extension for an earlier patent related to MIPLYFFA.

Importance 60.0 Sentiment 0.0

per

Neil F. McFarlane

Neil F. McFarlane, as President and CEO of Zevra Therapeutics, expressed satisfaction with the strengthened intellectual property protection for MIPLYFFA.

Importance 30.0 Sentiment 0.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard